India, Aug. 17 -- NEXGEL, Inc. (NXGL), a provider of hydrogel-based healthcare and consumer products, reported financial results for the second quarter ended June 30, 2026, highlighting progress in BioNX Surgical division and hospital channel expansion.
Second Quarter 2026 Results
Revenue for Q2 2026 totaled $3.69 million, compared to $2.88 million in Q2 2025, reflecting growth from the Celularity transaction and integration of BioNX Surgical operations.
Net loss for Q2 2025 was $2.87 million, compare with $0.67 million in Q2 2025, as integration costs and non-recurring charges weighed on results. The reported loss including:
-$756,554 of BioNX intangible asset amortization
-$273,710 of transaction-related expenses
-$144,495 tied to t...